109 related articles for article (PubMed ID: 16540168)
21. [Splenic marginal zone B-cell lymphoma with bilateral renal invasion after splenectomy].
Hoshino T; Iriuchijima H; Ogawa Y; Irisawa H; Jinbo T
Rinsho Ketsueki; 2008 Jan; 49(1):35-9. PubMed ID: 18277594
[TBL] [Abstract][Full Text] [Related]
22. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
23. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
24. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
Taverna JA; Lerner A; Bhawan J; Demierre MF
J Drugs Dermatol; 2007 Jul; 6(7):731-2. PubMed ID: 17763598
[TBL] [Abstract][Full Text] [Related]
25. Plasma cell leukemia masquerading as ALL-L3--a case report.
Tripathy K; Gouda KP; Chakrabarty S; Das AK; Mohanty R
Indian J Pathol Microbiol; 2005 Apr; 48(2):221-3. PubMed ID: 16758674
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
[TBL] [Abstract][Full Text] [Related]
27. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
[No Abstract] [Full Text] [Related]
28. [Acute plasma cell leukemia].
Monsalbe V; Domíngues C; Roa I; Busel D; González S
Rev Med Chil; 1989 Jan; 117(1):55-9. PubMed ID: 2641624
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
30. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab.
Westphal S; Hansson S; Mjörnstedt L; Mölne J; Swerkersson S; Friman S
Transplant Proc; 2006 Oct; 38(8):2659-60. PubMed ID: 17098031
[TBL] [Abstract][Full Text] [Related]
31. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Hanamura A; Hayakawa M; Naito K
Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
[TBL] [Abstract][Full Text] [Related]
32. Abrupt Development of Plasma Cell Leukemia in a Patient with Chronic Anemia under Follow-up.
Farzaneh MR; Moradi A; Ravanbod MR; Daghbashi M
Arch Iran Med; 2016 Jan; 19(1):75-7. PubMed ID: 26702753
[TBL] [Abstract][Full Text] [Related]
33. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
Bremer E; ten Cate B; Samplonius DF; Mueller N; Wajant H; Stel AJ; Chamuleau M; van de Loosdrecht AA; Stieglmaier J; Fey GH; Helfrich W
Cancer Res; 2008 Jan; 68(2):597-604. PubMed ID: 18199557
[TBL] [Abstract][Full Text] [Related]
34. [Primary diffuse large B-cell lymphoma of the bone marrow complicated with autoimmune hemolytic anemia and erythroid hypoplasia].
Sumi M; Ichikawa N; Shimizu I; Yotsumoto M; Ueno M; Kobayashi H
Rinsho Ketsueki; 2007 Jul; 48(7):571-5. PubMed ID: 17695307
[TBL] [Abstract][Full Text] [Related]
35. Early relapse after rituximab chemoimmunotherapy.
Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
[TBL] [Abstract][Full Text] [Related]
36. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
37. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
38. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
39. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
40. Resolution of IgM nephropathy after rituximab treatment.
Betjes MG; Roodnat JI
Am J Kidney Dis; 2009 Jun; 53(6):1059-62. PubMed ID: 19084309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
